Patent · US Active

Fecal microbiota composition for use in reducing treatment-induced inflammation

US12076350B2 · kind B2 · utility

0Cited by

0References

19Claims

0Family size

Assignee

MaaT PHARMA · FR

Inventors

Emilie PLANTAMURA · L'Essart Mador, FR
Cyrielle GASC · L'Essart Mador, FR
Benoît Levast · L'Essart Mador, FR
Lilia Boucinha · L'Essart Mador, FR
Corentin Le Camus · L'Essart Mador, FR
Carole SCHWINTNER · Val-de-Reuil, FR
Hervé AFFAGARD · L'Essart Mador, FR

Key dates

Filing date	Jul 19, 2019
Grant date	Sep 3, 2024
Priority date	—
Expiry date	Nov 14, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P29/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the use of fecal microbiota transplant for preventing and/or reducing systemic and gut treatment-induced inflammation in an individual in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.